Related Experiment Video
Updated: Feb 5, 2026

Using an Automated Hirschberg Test App to Evaluate Ocular Alignment
Published on: March 24, 2020
Fragile X and APP: a Decade in Review, a Vision for the Future
1Department of Neurology, University of Wisconsin-Madison, Medical Sciences Center, Room 3619, 1300 University Avenue, Madison, WI, USA. westmark@wisc.edu.
Abstract:
Fragile X syndrome (FXS) is a devastating developmental disability that has profound effects on cognition, behavior, and seizure susceptibility. There are currently no treatments that target the underlying cause of the disorder, and recent clinical trials have been unsuccessful. In 2007, seminal work demonstrated that amyloid-beta protein precursor (APP) is dysregulated in Fmr1KO mice through a metabotropic glutamate receptor 5 (mGluR5)-dependent pathway. These findings raise the hypotheses that: (1) APP and/or APP metabolites are potential therapeutic targets as well as biomarkers for FXS and (2) mGluR5 inhibitors may be beneficial in the treatment of Alzheimer's disease. Herein, advances in the field over the past decade that have reproduced and greatly expanded upon these original findings are reviewed, and required experimentation to validate APP metabolites as potential disease biomarkers as well as therapeutic targets for FXS are discussed.
Insights
Fragile X syndrome (FXS) research reveals amyloid precursor protein (APP) dysregulation. APP metabolites show promise as therapeutic targets and biomarkers for FXS, potentially improving treatment options.
Area of Science:
- Neuroscience
- Genetics
- Developmental Biology
Background:
- Fragile X syndrome (FXS) is a severe developmental disorder with no current treatments targeting its root cause.
- Previous research linked amyloid-beta protein precursor (APP) dysregulation in Fmr1KO mice to metabotropic glutamate receptor 5 (mGluR5).
Purpose of the Study:
- To review advances in FXS research over the past decade.
- To discuss the potential of APP and its metabolites as therapeutic targets and biomarkers for FXS.
- To explore the implications for Alzheimer's disease treatment.
Main Methods:
- Review of scientific literature and experimental findings.
- Analysis of APP dysregulation pathways in Fmr1KO mouse models.
- Discussion of potential therapeutic strategies and biomarker validation.
Main Results:
- Significant expansion and reproduction of original findings on APP dysregulation in FXS models.
- Identification of APP metabolites as potential biomarkers and therapeutic targets for FXS.
- Exploration of mGluR5 inhibitors' potential in Alzheimer's disease.
Conclusions:
- APP metabolites represent promising avenues for FXS therapeutic development and biomarker discovery.
- Further research is required to validate APP metabolites for clinical application in FXS.
- The findings suggest a potential link between FXS and Alzheimer's disease pathways.
Related Concept Videos
Vision
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Color Vision
Depth Perception and Spatial Vision
Longitudinal Research

